Interní Med. 2013; 15(11-12): 352-354

Advances in the treatment of viral hepatitis B and C

prof.MUDr.Petr Husa, CSc.
Klinika infekčních chorob LF MU a FN Brno, Brno

Acute hepatitis B is in most cases benign disease without necessity of antiviral therapy. Chronic hepatitis B viral infection can be treated

with pegylated interferon (PEG-IFN), tenofovir or entecavir. Standard of therapy in chronic hepatitis C naïve patients, infected with

genotype 1, is still combination of PEG-IFN and ribavirin (RBV), Triple combination therapy – boceprevir or telaprevir + PEG-IFN + RBV is

so far in the Czech Republic approved only for patients without sustained effect of initial dual PEG-IFN and RBV therapy.

Keywords: hepatitis B, hepatitis C, pegylated interferon, ribavirin, boceprevir, telaprevir, tenofovir, entecavir

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P. Advances in the treatment of viral hepatitis B and C. Interní Med. 2013;15(11-12):352-354.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Husa P, Plíšek S, Šperl J, Urbánek P, Galský J, Hůlek P, Kümpel P, Němeček V, Volfová M. Diagnostika a léčba chronické hepatitidy B. Doporučený postup České hepatologické společnosti a Společnosti infekčního lékařství České lékařské společnosti J. E. Purkyně. Duben 2009. Prakt Lék 2009; 89: 167-176.
    2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2012; 57: 167-185. Go to original source... Go to PubMed...
    3. Urbánek P, Husa P, Galský J, et al. Standardní diagnostický a terapeutický postup u chronické infekce virem hepatitidy C (HCV). Gastroent Hepatol 2012; 66(3): 214-229.
    4. Poordad F, McCone J jr, Bacon BR, et al. For SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195-1206. Go to original source... Go to PubMed...
    5. Bacon BR, Gordon SC, Lawitz E, et al. For HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1207-1217. Go to original source... Go to PubMed...
    6. Jacobson IM, McHutchinson JG, Dusheiko G, et al. For ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364(25): 2405-2416. Go to original source... Go to PubMed...
    7. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa 2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid virological response: final results of Phase 3 ILLUMINATE study. Hepatology 2010 52(S4): 401A-402A.
    8. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364(25): 2417-2428. Go to original source... Go to PubMed...
    9. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013; 58(4): 583-592. Go to original source... Go to PubMed...
    10. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887. Go to original source... Go to PubMed...
    11. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877. Go to original source... Go to PubMed...
    12. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58(4): 643-645. Go to original source... Go to PubMed...
    13. Poordad F, Lawitz E, Kowdley KV, at al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368(1): 45-53. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.